What is the March-In Right

Currently under federal law, The march-in right allows the US National Institutes of Health (NIH) to require a drug maker (whose research was federally funded) to license its patient to another party in order to “alleviate health and safety needs which are not being reasonable satisfied” or when the benefits of a drug are not available on “reasonable terms.” Read article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.